Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last SFr.100.40 CHF
Change Today +0.40 / 0.40%
Volume 3.9M
As of 11:43 AM 07/31/15 All times are local (Market data is delayed by at least 15 minutes).

Audit Committee* - novartis ag-reg (NOVN)

Name (Connections)Board RelationshipsTitleKey Developments
Enrico Vanni Ph.D. 35 RelationshipsVice Chairman, Chairman of Compensation Committee, Member of Audit & Compliance Committee and Member of Research & Development Committee 
Srikant Datar Ph.D. 53 RelationshipsNon-Executive Director, Chairman of Audit & Compliance Committee, Member of Compensation Committee and Member of Risk Committee 
Andreas von Planta Ph.D. 68 RelationshipsDirector, Chairman of Risk Committee, Member of Audit & Compliance Committee and Member of Governance, Nomination & Corporate Responsibilities Committee 
Dimitri Azar M.D., MBA 12 RelationshipsDirector, Member of Research & Development Committee and Member of Audit & Compliance Committee 

Compensation Committee* - novartis ag-reg (NOVN)

Name (Connections)Board RelationshipsTitle
Srikant Datar Ph.D. 53 RelationshipsNon-Executive Director, Chairman of Audit & Compliance Committee, Member of Compensation Committee and Member of Risk Committee
Ann Fudge 388 RelationshipsDirector, Member of Risk Committee, Member of Compensation Committee and Member of Governance, Nomination & Corporate Responsibilities Committee
Enrico Vanni Ph.D. 35 RelationshipsVice Chairman, Chairman of Compensation Committee, Member of Audit & Compliance Committee and Member of Research & Development Committee
William Winters 59 RelationshipsDirector and Member of Compensation Committee
NOVN Compensation vs. Industry
2.1M
468.0K
Chief Executive Officer
829.2K
291.7K
Chief Financial Officer
Share price activity for NOVARTIS AG-REG (NOVN)
52 Week Price Performance
NOVN
Industry Average

Nominating Committee* - novartis ag-reg (NOVN)

Name (Connections)Board RelationshipsTitleKey Developments
Pierre Landolt Ph.D. 27 RelationshipsIndependent & Non Executive Director and Chairman of Governance, Nomination & Corporate Responsibilities CommitteeNovartis Approves Dividend, Payable on March 5, 2015; Announces Board Changes
02/27/15
Andreas von Planta Ph.D. 68 RelationshipsDirector, Chairman of Risk Committee, Member of Audit & Compliance Committee and Member of Governance, Nomination & Corporate Responsibilities CommitteeNovartis Announces Board Changes
10/10/14
Ann Fudge 388 RelationshipsDirector, Member of Risk Committee, Member of Compensation Committee and Member of Governance, Nomination & Corporate Responsibilities CommitteeNovartis AG Appoints Bruno Strigini as President of Novartis Oncology
06/9/14

Corporate Governance Committee* - novartis ag-reg (NOVN)

Name (Connections)Board RelationshipsTitle
Ann Fudge 388 RelationshipsNon-Executive Director, Chairman of Audit & Compliance Committee, Member of Compensation Committee and Member of Risk Committee
Pierre Landolt Ph.D. 27 RelationshipsDirector, Member of Risk Committee, Member of Compensation Committee and Member of Governance, Nomination & Corporate Responsibilities Committee
Andreas von Planta Ph.D. 68 RelationshipsVice Chairman, Chairman of Compensation Committee, Member of Audit & Compliance Committee and Member of Research & Development Committee
NOVN and Competitor
Insiders vs. External
Board
0%
100%
Novartis AG
8%
92%
Amgen Inc.
7%
93%
Gilead Sciences Inc.
7%
93%
Nestlé S.A.
17%
83%
Allergan plc
8%
92%
Johnson & Johnson
Insiders
External Board Members

Executive Committee* - novartis ag-reg (NOVN)

Name (Connections)Board RelationshipsTitle
Raymund Breu Ph.D. 13 RelationshipsFormer Chief Financial Officer
Kevin Buehler 23 RelationshipsFormer Division Head of Alcon and Member of Executive Committee
George Gunn BVM&S, DVSM, MRCVS. 15 RelationshipsFormer Division Head of Animal Health and Member of Executive Committee
Alexandre Jetzer 13 RelationshipsFormer Non-Executive Director and Member of Executive Committee
Joerg Reinhardt Ph.D. 12 RelationshipsChairman and Chairman of Research & Development Committee
Jonathan Symonds CBE 59 RelationshipsFormer Advisor
Management Effectiveness Relative to the Industry
Return on Equity
0.7x
Return on Assets
0.8x
Return on Total Capital
0.7x
TEV/Total Revenue(LTM)
0.7x
*Data is at least as current as the most recent Definitive Proxy.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NOVN:VX SFr.100.40 CHF +0.40

NOVN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Allergan plc $331.15 USD +2.28
Amgen Inc $176.59 USD +4.90
Gilead Sciences Inc $117.86 USD -0.04
Johnson & Johnson $100.21 USD +0.37
Nestle SA SFr.73.20 CHF +0.30
View Industry Companies
 

Industry Analysis

NOVN

Industry Average

Valuation NOVN Industry Range
Price/Earnings 26.3x
Price/Sales 4.9x
Price/Book 3.2x
Price/Cash Flow 14.2x
TEV/Sales 4.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NOVARTIS AG-REG, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.